Vir Biotechnology, Inc. Common Stock (VIR)
Vir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to treat and prevent infectious diseases. Founded with a mission to enhance immune responses and improve healthcare outcomes, Vir leverages cutting-edge science in immunology and antibody technologies to address global health challenges, including viral infections such as influenza, HIV, and COVID-19.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 3, 2010 | $0.03 | 2010-11-03 | 2010-11-05 |
| September 17, 2010 | $0.03 | 2010-08-25 | 2010-08-27 |
| June 11, 2010 | $0.03 | 2010-05-12 | 2010-05-14 |
| March 19, 2010 | $0.03 | 2010-03-03 | 2010-03-05 |
| December 1, 2009 | $0.03 | 2009-11-06 | 2009-11-10 |
Dividends Summary
- Vir Biotechnology, Inc. Common Stock has issued 13 dividend payments over the past 3 years
- The most recent dividend was paid 5422 days ago, on December 3, 2010
- The highest dividend payed out to investors during this period was $0.03 per share
- The average dividend paid during this period was $0.03 per share.
Company News
Vir Biotechnology reported a Q2 2025 net loss of $0.80 per share, with revenues of $1.2 million. The company advanced its clinical pipeline in hepatitis delta and oncology, maintaining $892.1 million in cash reserves while continuing to invest in research and development.
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullis...
A more selective small-cap index has consistently outperformed the Russell 2000